Literature DB >> 17208233

Intracellular route and mechanism of action of ERB-hRNase, a human anti-ErbB2 anticancer immunoagent.

Claudia De Lorenzo1, Chiara Di Malta, Gaetano Calì, Fulvia Troise, Lucio Nitsch, Giuseppe D'Alessio.   

Abstract

Human anti-ErbB2 immunoRNase with Erbicin fused to HP-RNase (ERB-hRNase) is a fully human immunoRNase made up of human pancreatic RNase fused to a human anti-ErbB2 scFv. It binds selectively with high affinity to ErbB2-positive cells, and specifically inhibits their proliferation, in vitro and in vivo. An investigation of its mechanism of action and its intracellular destination has revealed that ERB-hRNase depends on its RNase activity for cytotoxic action; it reaches the cytosol directly from the endosomal compartment; it is inhibited by the cytosolic RNase inhibitor (cRI), but the levels that ERB-hRNase reaches in the cytosol neutralize cRI, thus inducing cell death by apoptosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17208233     DOI: 10.1016/j.febslet.2006.12.034

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  11 in total

1.  The nuclear transport capacity of a human-pancreatic ribonuclease variant is critical for its cytotoxicity.

Authors:  Pere Tubert; Montserrat Rodríguez; Marc Ribó; Antoni Benito; Maria Vilanova
Journal:  Invest New Drugs       Date:  2010-03-30       Impact factor: 3.850

2.  A novel fully human antitumor immunoRNase resistant to the RNase inhibitor.

Authors:  Gennaro Riccio; Chiara D'Avino; Ronald T Raines; Claudia De Lorenzo
Journal:  Protein Eng Des Sel       Date:  2012-12-11       Impact factor: 1.650

Review 3.  Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity.

Authors:  Thomas J Rutkoski; Ronald T Raines
Journal:  Curr Pharm Biotechnol       Date:  2008-06       Impact factor: 2.837

4.  Antitumor activity and toxicity of anti-HER2 immunoRNase scFv 4D5-dibarnase in mice bearing human breast cancer xenografts.

Authors:  Taras G Balandin; Evelina Edelweiss; Natalia V Andronova; Elena M Treshalina; Alexander M Sapozhnikov; Sergey M Deyev
Journal:  Invest New Drugs       Date:  2009-09-30       Impact factor: 3.850

5.  Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells.

Authors:  Chiara D'Avino; Rolando Paciello; Gennaro Riccio; Carmela Coppola; Melina Coppola; Paolo Laccetti; Nicola Maurea; Ronald T Raines; Claudia De Lorenzo
Journal:  Protein Eng Des Sel       Date:  2014-01-12       Impact factor: 1.650

6.  Engineered human angiogenin mutations in the placental ribonuclease inhibitor complex for anticancer therapy: Insights from enhanced sampling simulations.

Authors:  Xiaojing Cong; Christian Cremer; Thomas Nachreiner; Stefan Barth; Paolo Carloni
Journal:  Protein Sci       Date:  2016-05-19       Impact factor: 6.725

7.  A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours.

Authors:  M Borriello; P Laccetti; G Terrazzano; G D'Alessio; C De Lorenzo
Journal:  Br J Cancer       Date:  2011-05-10       Impact factor: 7.640

8.  Picornavirus RNA is protected from cleavage by ribonuclease during virion uncoating and transfer across cellular and model membranes.

Authors:  Elisabetta Groppelli; Hazel C Levy; Eileen Sun; Mike Strauss; Clare Nicol; Sarah Gold; Xiaowei Zhuang; Tobias J Tuthill; James M Hogle; David J Rowlands
Journal:  PLoS Pathog       Date:  2017-02-06       Impact factor: 6.823

9.  Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours.

Authors:  T Gelardi; V Damiano; R Rosa; R Bianco; R Cozzolino; G Tortora; P Laccetti; G D'Alessio; C De Lorenzo
Journal:  Br J Cancer       Date:  2010-01-05       Impact factor: 7.640

10.  Barnase as a new therapeutic agent triggering apoptosis in human cancer cells.

Authors:  Evelina Edelweiss; Taras G Balandin; Julia L Ivanova; Gennady V Lutsenko; Olga G Leonova; Vladimir I Popenko; Alexander M Sapozhnikov; Sergey M Deyev
Journal:  PLoS One       Date:  2008-06-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.